A carregar...
Phase III Trial of Irinotecan/Cisplatin Compared With Etoposide/Cisplatin in Extensive-Stage Small-Cell Lung Cancer: Clinical and Pharmacogenomic Results From SWOG S0124
PURPOSE: Irinotecan plus cisplatin (IP) improved survival over etoposide plus cisplatin (EP) in Japanese patients with extensive-stage small-cell lung cancer (E-SCLC). To confirm those results and discern the potential role of population-related pharmacogenomics (PG) in outcomes, we conducted a larg...
Na minha lista:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
American Society of Clinical Oncology
2009
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2684855/ https://ncbi.nlm.nih.gov/pubmed/19349543 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2008.20.1061 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|